

14th November 2022

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Dear Sir/Madam,

Stock Code: NSE: SHILPAMED/BSE-530549

Sub: Newspaper Publication of Un-audited Standalone and Consolidated Financial Results for the Quarter & Half Year ended 30th September, 2022

Further to our letter dated 11th November 2022 regarding approval of Un-audited Standalone and Consolidated Financial Results of the Company for the quarter & half year ended 30th September 2022, please find enclosed newspaper advertisements, published in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in Soodhimool (Kannada) and Business Line (English) on 13th November 2022.

This is for your information and updation.

Thanking you,

For Shilpa Medicare Limited

RITU
TIWARY
Digitally signed
by RITU TIWARY
Date: 2022.11.14
18:01:08 +05'30'

Ritu Tiwary
Company Secretary & Compliance Officer

Govt has spent ₹10-lakh cr to reach affordable fertilisers to farmers: PM

FARM BOOST. Dedicates urea plant at Ramagundam; no plan to privatise Singareni collieries, says Modi

KV Kurmanath
Hyderabad

Prime Minister Narendra Modi today dedicated to the nation the Ramagundam Fertilisers and Chemicals Limited's urea plant at Ramagundam, which has been revived with an investment of ₹6,538 crore. The plant has a capacity to produce 12.7 lakh tonnes of urea, catering to the needs of Telangana, Andhra Pradesh, Chhattisgarh and Maharashtra.

The Prime Minister, who was on a day's visit to Telangana, also laid the foundation stone for four road projects, which would be taken up with an outlay of ₹2,300 crore. Addressing a gathering after inaugurating the plant at Ramagundam, the Prime Minister said the country was producing 70 lakh tonnes of urea as the government had revived five factories. "We have spent ₹10-lakh crore to provide fertilisers to farmers at affordable prices. We are going to spend ₹2.5-lakh crore more this year for the purpose," he said. "The government is spending



NUTRIENT TO AGRI SECTOR. Prime Minister Narendra Modi dedicating to the nation RFCL's urea plant at Ramagundam

₹2,000 on each urea bag, but farmers are getting it for ₹270. Similarly, DAP fertiliser bags gets a subsidy of ₹2,500," he said. Stating that the coal sector had been plagued by scams involving

thousands of crores, he said the country as a whole and workers, the Centre has been focussing on an integrated approach to infrastructure development to ensure inclusive growth. He was addressing a public meeting in Visakhapatnam after laying the foundation stone and inaugurating development works in Andhra Pradesh involving investments of about ₹10,740 crore.

SINGARENI COLLIERIES Rebutting allegations that the Centre was trying to privatise the Singareni Collieries Company Limited (SCCL), the Prime Minister said there was no plan to privatise the public sector unit, in which the Telangana government owns 51 per cent equity. "The Centre cannot take any decision on the privatisation of SCCL on its own," he said.

Telangana Chief Minister K Chandrababoo Naidu skipped the meeting in the backdrop of the rivalry between the TRS and the BJP. The TRS had erected hoardings in Hyderabad and Ramagundam, reminding the Prime Minister about the promises made to the State at the time of bifurcation.

'Integrated infra development is key to inclusive growth'

G Naga Sridhar
Hyderabad

Prime Minister Narendra Modi on Saturday said the Centre has been focussing on an integrated approach to infrastructure development to ensure inclusive growth. He was addressing a public meeting in Visakhapatnam after laying the foundation stone and inaugurating development works in Andhra Pradesh involving investments of about ₹10,740 crore.

Investments were rising because of schemes and initiatives like Production Linked Incentive Scheme and GATI Shakti, the Prime Minister said, adding that the welfare of the poor was also being kept in mind. The youth was now accessing new opportunities thanks to the focus on sunrise sectors including drones and start-ups, he said.

APS TRANSFORMATION Referring to the economic crises in many countries, the Prime Minister said India was scripting a new story of development. Thanking the Prime Minister



BONHOMIE. Prime Minister Narendra Modi with Andhra Pradesh Chief Minister Jagan Mohan Reddy during the launch of developmental projects in Visakhapatnam on Saturday.

for his support to Andhra Pradesh, Chief Minister YS Jagan Mohan Reddy said the scars from his bifurcation eight years ago remained and supporting from the Centre would be vital. "We have been utilising every penny of our resources for the development of the State," he said, adding that his government would work with the Centre for the development of the State.

Ashwini Vaishnav, Minister for Railways, said the railways was undergoing a transformation with world-class facilities. "Vizag Railway Station will be developed to become a world class facility spending ₹446 crore," he said. The Prime Minister also approved new telephone towers in the State which would connect 4,668 villages, Vaishnav added. Modi inaugurated the U-field Onshore Deepwater block project of ONGC and the Narasannapeta-Pathanam section of NH-326A as part of the Srikakulam-Gajapati Corridor. He laid the foundation for the Andhra Pradesh section of the six-lane graded Raipur-Visakhapatnam Economic Corridor, and modernisation and upgrade of the Visakhapatnam Fishing Harbour.

Aurobindo Pharma's Q2 net down 41% due to unfavourable macros

Our Bureau
Hyderabad

Aurobindo Pharma's net profit declined 41 per cent at ₹499 crore in the second quarter ended September 30 compared to ₹697 crore in the corresponding previous quarter.

The total revenue of the Hyderabad-based company declined 3.4 per cent at ₹5,739 crore from ₹5,941 crore in the year-ago period.

"Our Q2FY23 performance was subdued mainly due to the macro-environmental factors and higher

"The Q2 was subdued mainly due to the macro-environment and higher competitive intensity for some products in the United States."

competitive intensity for some products in the US. However, we are confident that our robust pipeline of new products will provide impetus to the future growth trajectory," K

Nithyananda Reddy, Vice-Chairman and Managing Director, said in a release on Saturday.

NOD FOR NINE ANDAS The Research & Development (R&D) spend of the company was pegged at ₹276 crore, accounting for 4.8 per cent of the revenue.

Aurobindo Pharma received final approval for nine Abbreviated New Drug Application (ANDAs) including five injectable products from the US Food and Drug Administration during the quarter, the release said.

At halfway point, many key issues unresolved at UN climate talks

Press Trust of India
Sharm El-Sheikh

As the UN climate talks in Egypt near the halfway point, negotiators are working hard to draft deals on a wide range of issues they will put to ministers next week in the hope of getting a substantial result by the end.

Top US negotiator indicated that a planned meeting on Monday between US President Joe Biden and President Xi Jinping of China on the sidelines of the Group 20 meeting in Bali could also provide an important signal for the climate talks as they go to the home stretch.

The two-week meeting in Sharm El-Sheikh started with strong appeals from world leaders for greater efforts to curb greenhouse gas emissions and help poor nations cope with global warming.

Scientists say the amount of greenhouse gases being pumped into the atmosphere needs to be halved by 2030 to meet the goals of the Paris Climate Accord.

The 2015 pact set a target of ideally limiting temperature rise to 1.5 degrees Celsius (2.7 Fahrenheit) by the end of the century, but left it up to countries to decide how they want to do so.

With impacts from climate change already felt across the globe, particularly by the world's poorest, there has also been a push by campaigners and developing nations for rich polluters to stump up more cash.

ASHOKA BUILDCON LIMITED

Regd. Office: S. No. 861, Ashoka House, Ashoka Marg, Vadala, Nasik - 422 011
Phone No: 0253-663705, Fax: +0253 2236704, Email: investors@ashokabuildcon.com, Website: www.ashokabuildcon.com

EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED 30th SEPTEMBER 2022

Particulars	Quarter ended				Half Year Ended		Year ended
	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Total Income from operations	180,768.67	187,856.23	126,488.97	368,624.90	254,802.44	594,580.22	
Net Profit/(Loss) for the period before tax	10,389.53	19,294.67	12,646.10	29,684.20	25,096.23	93,220.95	
Net Profit/(Loss) for the period after tax and share of profit/(loss) of associates	6,566.47	13,465.81	7,809.73	20,032.28	15,759.81	77,140.60	
Net Profit/(Loss) for the period attributable to shareholders of the company	6,366.20	13,455.40	7,993.80	19,821.60	16,015.51	77,856.10	
Total comprehensive income/(loss) for the period (comprising profit/(loss) for the period (after tax) and other comprehensive income/(loss) (after tax)	6,619.00	13,454.33	7,805.91	20,073.33	15,749.37	77,271.02	
Total comprehensive income/(loss) attributable to shareholders of the company	6,418.02	13,443.66	7,990.89	19,861.68	16,005.98	77,984.51	
Paid-up equity share capital (face value of Rs.5/- each)	14,036.16	14,036.16	14,036.16	14,036.16	14,036.16	14,036.16	
Other Equity							
Earnings per share (face value of Rs.5/- each)							
Basic Rs.	2.27	4.79	2.85	7.06	5.71	27.73	
Diluted Rs.	2.27	4.79	2.85	7.06	5.71	27.73	

KEY STANDALONE FINANCIAL INFORMATION FOR THE PERIOD ENDED 30th SEPTEMBER 2022

Particulars	Quarter ended			Half Year Ended		Year ended	
	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21		31-Mar-22
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited		Audited
Total Income from operations	128,026.01	147,904.92	91,713.91	275,930.93	192,854.21	459,145.66	
Profit/(Loss) before tax	8,732.73	13,926.92	12,706.95	26,176.55	22,359.07	82,239.07	
Profit/(Loss) after tax	6,546.00	10,432.77	9,559.41	16,978.77	19,692.65	(30,864.82)	

- Notes:**
- The financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated July 05, 2016.
 - The above is an extract of the detailed format of unaudited consolidated financial results for the quarter and half year ended September 30, 2022 filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2022 is available on the Company's website i.e. www.ashokabuildcon.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com.
 - The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at the respective meetings held on November 11, 2022.

Place: Nashik
Date: November 11, 2022

By Order of the Board
For Ashoka Buildcon Limited
Sd/-
(Satish D. Parakh)
Managing Director
DIN : 00112324

By Dec-end, HDFC Bank to sell 3.2% in Lentra AI for ₹54 crore

Our Bureau
Mumbai

HDFC Bank has entered into an agreement to sell 73,941 shares of Lentra AI Private Limited at ₹7326 per share, equivalent to 3.2 per cent stake in the company, for a total consideration of ₹54.2 crore.

As per the agreement signed on Friday, the sale will be completed by the end of December, the private sector lender informed the exchanges.

ONA DILUTED BASIS Following the share sale, HDFC Bank will hold 6.6 per cent stake in the company,



HDFC Bank will hold 6.6% stake in the firm post the sale

on a fully diluted basis. Lentra AI is in the business of designing, developing, licensing and implementation of software products for the financial services sector. Incorporated in July

2018, the company had a turnover of ₹72 crore in FY22 and reported a loss of ₹52 crore for the financial year.

HDFC Investments Ltd, is also a shareholder of Lentra, and this transaction is being done "on an arm's length basis", the bank said.

businessline.
Disclaimer: Readers are requested to verify & make appropriate enquiries to verify the authenticity of any advertisement published in this newspaper. THE PUBLISHING PVT LTD, the Publisher & Owner of this newspaper does not vouch for the authenticity of any advertisement or advertisement or services. In no event can the Owner, Publisher, Printer, Editor, Directors, Employees of this newspaper/company be held responsible for any claims and/or damages for advertisements in this newspaper.

SHILPA MEDICARE LIMITED													
Registered office # 12-6-21/A-1, Hyderabad Road, Raichur-584135													
Website - www.shilpa.com, Email - info@shilpa.com, Telephone - +91-8532-238704, CIN No. - LB5110KA1987PLC008739													
Extract of the Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30.09.2022 (Rs. in Lakhs, except per equity share data)													
Sl. No	Particulars	STANDALONE					CONSOLIDATED						
		Quarter Ended 30-09-2022 (Unaudited)	Half Year Ended 30-06-2022 (Unaudited)	Quarter Ended 30-09-2021 (Unaudited)	Half Year Ended 30-06-2021 (Unaudited)	Year Ended 30-09-2021 (Audited)	Quarter Ended 30-09-2022 (Unaudited)	Half Year Ended 30-06-2022 (Unaudited)	Quarter Ended 30-09-2021 (Unaudited)	Half Year Ended 30-06-2021 (Unaudited)	Year Ended 31-03-2022 (Unaudited)	Year Ended 31-03-2021 (Audited)	
1	Total Income from Operations	6,873.08	6,083.42	9,124.71	12,956.48	19,650.78	35,695.18	28,290.53	26,115.66	29,527.12	52,406.19	53,282.78	114,552.27
2	Net Profit before tax, non controlling interest & share in profit/(loss) of joint venture / associates (before exceptional items)	(2,319.85)	405.01	48.11	(1,914.63)	1,310.95	1,867.68	(2,019.63)	(333.52)	(2,368.28)	(2,353.15)	2,960.44	9,713.40
3	Net Profit before tax, non controlling interest & share in profit/(loss) of joint venture / associates (after exceptional items)	(2,378.18)	405.01	939.01	(1,973.16)	2,201.85	2,748.58	(2,239.22)	(406.82)	3,144.82	(2,646.04)	3,661.99	10,226.47
4	Net Profit after tax, non controlling interest & share in profit/(loss) of joint venture / associates (after exceptional items)	(1,962.53)	385.44	1,006.43	(1,577.08)	1,638.04	2,015.83	(1,866.30)	84.85	1,996.04	(1,781.44)	2,154.81	6,066.23
5	Total Income (including other comprehensive income/(loss))	(1,717.43)	10,952.90	4,366.96	9,235.48	7,039.70	13,980.28	(1,864.37)	230.90	1,998.79	(1,833.47)	2,313.63	5,929.90
6	Equity Share Capital	868.02	868.02	815.27	868.02	815.27	868.02	868.02	868.02	815.27	868.02	815.27	868.02
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet at Other Equity	-	-	-	-	-	205,668.77	-	-	-	-	-	181,351.48
8	Earnings Per Share (of Rs. 1/- each) (for continuing operations) - (in Rs)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)	(Not Annualised)
1)	Basic:	(2.28)	(0.44)	1.23	(1.82)	2.01	2.41	(2.15)	0.10	2.45	(2.05)	2.64	7.26
2)	Diluted:	(2.28)	(0.44)	1.23	(1.82)	2.01	2.41	(2.15)	0.10	2.45	(2.05)	2.64	7.26

NOTES:

- The above is an extract of the detailed format of unaudited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosures Requirements) Regulations, 2015. The full format of the unaudited financial results is available on the investor section of our website www.shilpa.com and under corporate section of BSE Limited and National Stock Exchange of India Limited.
- The above results have been reviewed by the Audit Committee and approved by the Board of Director at its meeting held on 11 November, 2022.

For and on behalf of the Board of Directors
Ompakash Inani
Chairman

GAYATRI BIOORGANICS LIMITED												
Regd. Office: B3, Third Floor, 6-3-1080, T.S.R. Towers, Rajahmundry, Somajiguda, Hyderabad-500 082, Telangana, India. Website: www.gayatribioorganics.com												
CIN: L24110TG1991PLC013512												
Extract of the Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2022 (Rs. in Lakhs)												
Particulars	STANDALONE					CONSOLIDATED						
	Quarter ended 30.09.2022 (Unaudited)	Half Year ended 30.06.2022 (Unaudited)	Quarter ended 30.09.2021 (Unaudited)	Half Year ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Unaudited)	Quarter ended 30.09.2022 (Unaudited)	Half Year ended 30.06.2022 (Unaudited)	Quarter ended 30.09.2021 (Unaudited)	Half Year ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Unaudited)	Year ended 31.03.2021 (Audited)	
Total Income from Operations	-	-	-	-	-	-	-	-	-	-	-	-
Net Profit/(Loss) for the period (before Tax, Exceptional and Extra Ordinary Items)	(23.72)	(16.22)	(13.07)	(39.94)	(25.55)	(49.61)	(23.72)	(16.22)	(13.07)	(39.94)	(25.55)	(49.61)
Net Profit/(Loss) for the period before tax (after Exceptional and Extraordinary Items)	(23.72)	(16.22)	(13.07)	(39.94)	(25.55)	(49.61)	(23.72)	(16.22)	(13.07)	(39.94)	(25.55)	(49.61)
Net Profit/(Loss) for the period after tax (after Exceptional and Extraordinary Items)	(45.19)	(16.22)	(13.07)	(61.41)	(25.55)	(49.61)	(45.19)	(16.22)	(13.07)	(61.41)	(25.55)	(49.61)
Total comprehensive income for the period (Comprising Profit/(Loss) for the period (after tax) and other comprehensive income (after tax)*	(45.19)	(16.22)	(13.07)	(61.41)	(25.55)	(49.61)	(45.19)	(16.22)	(13.07)	(61.41)	(25.55)	(49.61)
Equity Share Capital	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81	7,878.81
Earnings Per Share (of ₹10/- each) (for continuing and discontinued operations) Basic and Diluted (in ₹)	(0.06)	(0.02)	(0.02)	(0.08)	(0.03)	(0.06)	(0.06)	(0.02)	(0.02)	(0.08)	(0.03)	(0.06)

NOTE:

The above is an extract of the detailed format of the Quarterly Financial Results for the Quarter and Half Year ended September 30, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Unaudited Financials Prepared. The full format of the said quarterly financial results is available on the Stock Exchange websites (www.bseindia.com) and on Company's website: www.gayatribioorganics.com

Place: Hyderabad
Date: November 12, 2022

By Order of the Board of Directors
Sd/-
Chairman

ಮಾಡುವುದಾಗಿ ಹೇಳಿಕೆ ನೀಡಿರುವ ಮೇಕೆಕಂಠ ವಿರುದ್ಧ ಎಫ್‌ಐಆರ್ ದಾಖಲಿಸಿ ಕೂಡಲೇ ಬಂಧಿಸುವಂತೆ ಆಗಬಹುದು.

ಈ ಸಂದರ್ಭದಲ್ಲಿ ಶಾಸಕ ವಿನಿಷಾ ಫಾತಿಮಾ, ಮಾಜಿ ವಿಧಾನ ಪರಿಷತ್ ಮಾಜಿ ಸದಸ್ಯರಾದ ತಿಪ್ಪಣ್ಣ ಕಮಕನೂರ್, ಅಲ್ಲಮಪ್ಪಳ್ಳು ಪಾಟೀಲ್, ಮುಖಂಡರಾದ ನೀಲಕಂಠರಾವ್ ಮೂಲಗೆ, ರೇವು ನಾಯಕ ಬೆಳಮಗಿ, ಶರಣ ಕುಮಾರ್ ಪೋದಿ, ಚೇತನ್ ಗೋಪಾಯಕ, ಸಂತೋಷ್ ಪಾಟೀಲ್, ಚಂದ್ರಿಕಾ ಪರಮೇಶ್ವರ್, ಲಕ್ಷ್ಮಣ ಜಮಾದಾರ, ರಾಜೇಶ್ ಗುತ್ತೇದಾರ್, ಶಿವಾನಂದ ಹೊಸಗುಂಟೆ, ಲಿಂಗರಾಜ ಕಣ್ಣೆ ಸಚಿನ್ ಶಿರವಾಳ ಸೇರಿದಂತೆ ಸೂಲಾಡು ಕಾರ್ಯಕರ್ತರು ಭಾಗವಹಿಸಿದ್ದರು.

(continuing operations) - (in Rs)	Annualised	Annualised	Annualised	Annualised	Annualised	Annualised	(not Annualised)	Annualised	Annualised	Annualised	Annualised	Annualised
11 Basic:	(2.26)	(0.44)	1.23	(1.82)	2.01	2.41	(2.15)	0.10	2.45	(2.05)	2.64	7.26
21 Disintest:	(2.26)	(0.44)	1.23	(1.82)	2.01	2.41	(2.15)	0.10	2.45	(2.05)	2.64	7.26

Notes:

- The above is an extract of the detailed format of unaudited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the unaudited financial results are available on the Investor section of our website www.vbshilpa.com and under corporate section of BSE Limited and National Stock Exchange of India Limited.
- The above results have been reviewed by the Audit Committee and approved by the Board of Director at its meeting held on 11 November, 2022

Date: 12/11/2022
Place: H Raichur

For and on behalf of the Board of Directors
Sd/
Omprakash Inani
Chairman